We identified in an unbiased manner a gene-set upregulated by estradiol and downregulated by Runx2 in an MCF7 breast cancer (BCa) culture model, whose short-term response to letrozole in tumor biopsies correlated with future tumor growth better than the responsiveness of hormone-regulated gene-sets defined regardless of Runx2; initial decrease in the expression of these genes in patients receiving letrozole therapy correlated most significantly with Ki67 index and tumor size reduction assessed months later. Many of the genes encoded components of the mitotic polo-like kinase pathway. Reciprocal antagonism between the mitogenic properties of estradiol and the anti-mitogenic properties of Runx2 should be further studied as a potential basis for the development of predictive strategies and identification of novel therapeutic targets for BCa. Research.
Statement of Translational Relevance
We identified in an unbiased manner a gene-set upregulated by estradiol and downregulated by Runx2 in an MCF7 breast cancer (BCa) culture model, whose short-term response to letrozole in tumor biopsies correlated with future tumor growth better than the responsiveness of hormone-regulated gene-sets defined regardless of Runx2; initial decrease in the expression of these genes in patients receiving letrozole therapy correlated most significantly with Ki67 index and tumor size reduction assessed months later. Many of the genes encoded components of the mitotic polo-like kinase pathway. Reciprocal antagonism between the mitogenic properties of estradiol and the anti-mitogenic properties of Runx2 should be further studied as a potential basis for the development of predictive strategies and identification of novel therapeutic targets for BCa.
Introduction.
The mitogenic effect of estrogens in breast epithelial cells is one of the best examples of hormonal carcinogenesis. Which of the many primary and secondary estrogen-responsive genes in breast epithelial cells drive hormonal carcinogenesis is difficult to discern. Although genes such as c-Myc, cyclin D and cyclin E have been implicated in estrogen-driven breast cancer (BCa) (1) , there is limited understanding of why some are better correlated than others with disease progression and drug responsiveness. Recent high throughput gene expression studies have led to the identification of gene groups, whose baseline mRNA levels and hormone responsiveness correlated well with clinical and histological features of disease progression (2-6). Interestingly, first-generation prognostic gene signatures were enriched for proliferation-and cell cycle-related genes, and were particularly valid for estrogen receptor alpha (ERα)-positive tumors (7, 8) . Better understanding of the biological significance of such gene signatures will potentially lead to novel pharmacological approaches targeting key molecular nodes that regulate BCa progression.
The Runx family of mammalian transcription factors plays fundamental roles in the differentiation of osteoblasts and chondrocytes (Runx2) (9) , hematopoietic cells (Runx1) (10, 11) and neurons (Runx3) (12) . Runx proteins are also increasingly implicated in cancer progression, both positively and negatively (13, 14) . Contrasting their pro-metastatic role, which was mostly studied in advanced breast and prostate cancer (14) (15) (16) (17) (18) (19) (20) , Runx proteins are well known for their tumor suppressor properties. Runx3 is a bona fide tumor suppressor gene, whose methylation contributes to gastric cancer (21) (22) (23) ; ablation of Runx1 activity leads to leukemia (24, 25) ; and Runx2 inhibits cell cycle progression in osteoblasts and prostate cancer cells (20, (26) (27) (28) .
Runx2 physically interacts with the DNA-binding domains of both ERα and the androgen receptor. These interactions usually result in reciprocal inhibition of the respective transcriptional activation activities (29) (30) (31) although different outcomes have been reported (32) (33) (34) (35) . The physical interaction between ERα and Runx2 (29) , and our more recent observation that E2 independently regulates half Author Manuscript Published OnlineFirst on December 6, 2011; DOI: 10.1158/1078-0432.CCR- of the Runx2-responsive genes in BCa cells (see herein), led to the speculation that the oncogenic potential of estradiol in breast epithelial cells might be related in part to antagonizing Runx2. In the present study, we first define gene sets coregulated by estrogen and Runx2 signaling in BCa cells in vitro. Then, by correlating expression pattern of these genes in BCa tumor biopsies with clinical response to aromatase inhibition therapy, we show that genes up-regulated by E2 and down-regulated by Runx2 are more informative than those defined in vitro based on their response to E2 alone.
Materials and methods

Establishment and maintenance of Runx2 expressing MCF7 BCa cells:
MCF7 BCa cells were obtained from the American Type Culture Collection. To establish MCF7 cell subline that conditionally express Runx2, we employed the recently described lentivirus-based pSLIK vector system, which allows tight doxycycline (dox)-inducible, RNA PolII-mediated transcription of a gene of interest (36) . Lentiviral particles encoding dox-inducible Flag-Runx2 (MASN isoform, type-2) and the Hygromycin B selection marker were constructed and packaged as previously described (20) . Transduced MCF7/Rx2 dox cells were selected in DMEM containing 10% FBS and 100 μg/ml Hygromycin B (GIBCO, Carlsbad, CA).
Western blot analysis. Proteins were separated on 10% SDS-PAGE and
Western blotting was performed using as primary antibodies mouse monoclonal anti-FLAG M2 (Sigma, St. Louis, MO), mouse monoclonal anti-Runx2 (Invitrogen, Carlsbad, CA) and goat anti-GAPDH (V-18) (Santa Cruz Biotechn., Inc, Santa Cruz, CA). After incubation with either horseradish peroxidase-conjugated goat anti-mouse secondary antibodies (sc2031) or donkey anti-goat antibodies (sc2020) from Santa Cruz Biotech., Inc., proteins were visualized with enhanced Chemiluminescence Plus western blotting detection kit (GE Healthcare UK limited, UK).
Immunofluorescence. Runx2 and ERα were visualized with the respective primary antibodies and secondary antibodies conjugated to either rhodamine or and plated over 0.5% base agar at a density of 5000 cells/well in 6 well plates.
Cells were incubated at 37C° with media change every two days and stained with 0.005% Crystal violet after 21 days of incubation. Colonies were counted using a dissecting microscope.
High-throughput gene expression analyses:
Two days before treatment MCF7/Rx2 dox cells were switched to phenol red-free DMEM containing 5% CSS.
Cells were treated with 0.5 µg/ml dox to induce Runx2 expression and/or with 10 nM E2. After 48h of treatment, RNA was extracted using Aurum Total RNA Mini Kit (BioRad, Hercules, CA) and submitted to the Southern California Genotyping Consortium (SCGC) for microarray analysis using HumanRef-8 v3.0 Expression BeadChips (Illumina Inc, CA). Raw data processing was performed using GenomeStudio (Illumina Inc) and extended analyses were performed using Partek Genomics Suite™ 6.6 (Partek, Inc, MO), or the R 2.11.1 package (http://cran.rproject.org), as indicated. Comparisons between gene expression under the various treatment conditions were performed by one-way ANOVA and differentially expressed genes were defined based on two criteria: an FDR-adjusted p value <0.05 and a fold change ≥1.3-fold. Hierarchical clustering was statistically assessed based on average silhouettes distance, average Pearson gamma, entropy, and within-between cluster ratio (see Supplemental Table 1 
Gene expression analysis of preoperative letrozole (POL) study:
The openlabel, multicenter phase II POL trial has been previously described (40) . Eligible hormone receptor-positive patients were administered 2.5 mg oral letrozole daily for 16 to 24 weeks before surgery, with biopsies taken at baseline and after 4 weeks of treatment, with change in proliferation marker Ki67 being as one of the primary outcomes of response. Using RNA extracted from the biopsies, gene expression profiles were generated on Agilent 4x44K whole human genome platform on 80 patients at baseline while 58 had paired four-week on-treatment gene expression profiling. Probe-level gene expression data were collapsed to the gene level by median representative and standardized by median-centering and robust scaling by inter-quartile range. All statistical analysis was carried out in R 2.11.1 (http://cran.r-project.org) and all tests were two-sided at the 5% significance level unless otherwise noted. The detailed description of the POL data analyses and independent letrozole study GSE5462 downloaded from GEO (41) is provided in Supplementary materials. ( Figure 3A and Supplemental Table 4 ). This is graphically demonstrated in Figure   3A by the larger number of data points below versus above the diagonal in the right half of the scatter-plot. The fraction of genes where E2 attenuated Runx2-mediated stimulation progressively increased from 0.7 for genes stimulated by <1.5-fold to 0.9 for genes stimulated by ≥3-fold ( Figure 3A , bar graph and Supplemental Table 4 ). That E2 attenuated the Runx2-mediated stimulation of gene expression is equally demonstrable when counting only the statistically significant changes (Supplemental Table 4 ). Similarly, E2 attenuated the inhibitory effects of Runx2 on genes expression ( Figure 3A , left half, and Supplemental Table 4 ). Exceptions to the attenuation phenomenon, however, were numerous, and are represented in Figure 3A by data points above the diagonal for doxstimulated genes and below the diagonal for dox-repressed genes. Similar analysis in the reciprocal orientation revealed that Runx2 modulated E2-mediated regulation of gene expression in a locus-specific manner, with attenuation again being the predominant mode of interaction ( Figure 3B ). These results are consistent with our original observation of E2-mediated inhibition of Runx2 activity (29) , but suggest two amendments. First, while attenuation of Runx2 activity by E2 was observed for the vast majority of genes strongly responding to Runx2, more exceptions were observed for genes that Runx2 stimulated or inhibited only mildly ( Figure 3A , bar graphs). Second, in the reciprocal orientation, Runx2 generally attenuated the responses to E2, in particular for E2-inhibited genes ( Figure 3B ). In both orientations, the outcomes of the interactions were gene-dependent. Table 5 ). As shown in Figure 4B , we observed a significant negative correlation between the D-only  and E-only  metagenes in each of these three independent cohorts. The negative correlation likely reflects the E2-mediated attenuation of the Runx2 response ( Figure 3A) and/or the Runx2-mediated attenuation of the E2 response ( Figure 3B -11-1530 in the absence of the other stimulus ( Figure 4A regard to their letrozole response and the correlation with clinical outcome in the WU-POL study.
Results
Establishment of MCF7/Rx2
Gene expression data from
We initially redefined metagenes I-IV, consisting of the respective genes in Clusters I-IV from the Illumina Beadchip analysis of the MCF7/Rx2 dox cells ( Figure   5A ), which were also represented in the Agilent microarrays employed in the WU-POL study (Supplementary Table 6 ). Figure 6A We further tested the correlation between the initial letrozole response in the expression of Cluster IV genes and tumor phenotype in an independent study (41, 45) . Changes in tumor gene expression before versus after two weeks of letrozole were first determined from the corresponding GSE5462 trial dataset (41) in a similar fashion to that described above for the POL study. Because this study did not include Ki67 staining, the patients with high versus low Cluster IV response were compared in terms of the efficacy of letrozole in reducing tumor volume (45) .
As shown in Figure 6D Table 8 ).
Discussion
The nuclear hormone receptor ERα and Runx family transcription factors play important roles in BCa, but little is known about their functional interaction. Table   3 ) and the immunofluorescence results (Figure 1 ) suggest that Runx2 inhibits ERα expression. Runx2 may also destabilize ERα similar to Runx3 (23) . Yet another mechanism could be the physical interaction between ERα and Runx2, which may result not only in decreased association of Runx2 with its target genes (29) , but also decreased association of ERα with its targets. In support of this idea, reanalysis of data from two recent studies (46, 47) indicated that genomic ERα target genes are more likely to be antagonized by Runx2 than non-genomic targets (Supplemental Table 9 ). While the relative contribution of each of these mechanisms is under investigation, the global reciprocal inhibitory effects between estrogen and Runx2 signaling observed in vitro (Figure 3 represent a critical regulatory node where the mitogenic property of E2 meets the anti-mitogenic property of Runx2. It is tempting to speculate that the direct opposition between E2 and Runx2 signaling at this node (Supplemental Figure 1) renders Cluster IV a sensor for the status of interaction between E2 and Runx2 signaling. Tumors with the highest tension between the two poles will respond to loss of E2 signaling with the sharpest decline in the expression of Cluster IV genes. In turn, unopposed Runx activity after letrozole treatment of these tumors will most effectively suppress their growth (Figure 6 ). Unlike the response of Cluster IV to letrozole treatment, no significant correlation was observed between clinical outcome and the baseline expression levels of Cluster IV, Runx2, Runx2-resposive genes, or E2-responsive genes (data not shown).
Cluster IV is enriched in genes associated with the mitotic polo-like kinase pathway, such as PLK4, CDC2, CCNB2, KIF11, PRC1 and PTTG1 (Supplemental Table 6 and Supplemental Figure 1 ), which regulates multiple mitotic events, including centrosome maturation, bipolar spindle formation, DNA damage adaptation, mitotic entry, activation of anaphase promoting complex, and cytokinesis, processes that must be well balanced to ensure normal mitotic progression and cell division (48) . Polo-like kinase 4 (PLK4) in particular plays a crucial role in centriole duplication, cytokinesis and maintenance of chromosomal stability, and deregulation of PLK4 has been implicated in carcinogenesis (48) .
Previous reports showed that estrogens stimulate and letrozole inhibits genes regulating mitotic spindle formation and cell proliferation (41, 49) . Therefore, Research.
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